Skip to content

Investigating the Effects of a Haskap Berry Supplement on Cognitive Health

Investigating the Cognitive, Vascular, and Metabolic Benefits of a Vitamin- and Mineral-Enhanced Haskap Berry Dietary Supplement

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07119788
Acronym
HACVAC
Enrollment
90
Registered
2025-08-13
Start date
2025-06-19
Completion date
2026-04-30
Last updated
2025-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognition

Keywords

Cognition, Mood, Stress, Vascular, Blood glucose, Haskap berries

Brief summary

This study aims to investigate the postprandial (2h) and longer term (4 week) effects of a haskap berry supplement on cognitive, vascular, and metabolic function in healthy ageing adults aged 50+.

Detailed description

This project aims to investigate the acute benefits (during the immediate post prandial period up to 2 hours) and chronic benefits (following 4 weeks daily supplementation) of a vitamin- and mineral-enhanced haskap berry supplement made from freeze-dried, powdered haskap berries. The main objective of this study is to trial the product in older adults aged 50+ to determine any cognitive, metabolic, or cardiovascular benefits over and above haskap powder alone or a placebo powder. The study will involve a screening visit and two testing visits, 4 weeks apart. For the 24 hours prior to each test visit, participants are asked to follow a low polyphenol diet. They are requested not to consume any food or drinks except water after 8.30pm, and on the morning of test visits to only consume one slice of buttered white toast and a glass of water prior to attending the visit. During the testing visits, cognitive and mood battery tests (to include measures of memory, executive functions, and stress, will be taken at baseline, at 2 hours following the consumption of the supplement as part of a meal, and again at 4 weeks following daily consumption of the supplement added to their usual diet. Blood glucose finger pricks will be recorded at each time point along with FMD (a measure of vascular reactivity).

Interventions

DIETARY_SUPPLEMENTPure haskap berry powder

6g serving of a pure, freeze-dried haskap berry powder

DIETARY_SUPPLEMENTPlacebo

6g serving of a calorie-matched powder, artificially coloured and flavoured to resemble berry powder

DIETARY_SUPPLEMENTVitamin-and mineral-enhanced haskap berry powder

6g serving of a vitamin- and mineral-enhanced haskap berry powder (fortified with potassium iodide, zinc bisglycinate, vitamin B5, and vitamin B12

Sponsors

Haskapa Ltd
CollaboratorUNKNOWN
University of Reading
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Intervention model description

Participants will be allocated to receive either a vitamin- and mineral-enhanced haskap berry powdered supplement, pure haskap berry powder, or a calorie matched placebo powder

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* 50+ years old * Fruit & veg intake less than or equal to 4 servings per day * Adequate English language and visual & auditory acuity to perform the cognitive tasks * Normal BMI for age

Exclusion criteria

* Being diagnosed with psychological or psychiatric disorders * ADHD or dyslexia * Any food allergy or intolerance * Use of medications and dietary supplements that may impact study results * Antibiotic use within the last 3 months * Adherence to vegan or vegetarian diets, or other specific diets that may impact study outcomes * Conditions altering absorption of nutrients (e.g. celiac disease) * Being diagnosed with cardiometabolic disease (including type II diabetes and cardiovascular disease), or suffer from untreated hypertension or thrombosis related disorders * Taking blood thinners

Design outcomes

Primary

MeasureTime frameDescription
Delayed recall (Rey Auditory Verbal Learning Task)BaselineThe RAVLT is a verbal learning task that presents participants with 15 words (list A) 5 times, giving participants one minute after each presentation to recall as many words as they can from the list. After 5 presentations, a new list (list B) is presented and recalled, and finally participants are asked (without hearing list A again) to recall as many words as they can from list A. After a 30 minute period, participants are asked to think back to the task and recall as many words as possible from list A only, providing a measure of delayed recall.

Secondary

MeasureTime frameDescription
Rate of learning (Rey Auditory Verbal Learning Task)BaselineThe RAVLT is a verbal learning task that presents participants with 15 sequential words (list A) 5 times, giving participants one minute after each presentation to recall as many words as they can from the list. Scores are recorded as a percentage of accuracy, and the rate of learning is determined through change in accuracy across the 5 recalls.
Word recognition (Rey Auditory Verbal Learning Task)BaselineFollowing the delayed word recall, words from list A, list B and novel words are displayed sequentially on the screen and participants are asked to indicate which words were from list A only.
Modified Attention Network Task (MANT)BaselineThis task examines execution function, attention and inhibition. Participants respond to a centrally presented target arrow pointing to the left or the right by pressing the corresponding key on the keyboard. The target arrow is flanked by arrows that point in the same (congruent) or opposite (incongruent) direction. Previous studies have found that participants show larger latencies and more errors on incongruent trials when compared with congruent trials due to the conflicting interference of the incongruently facing arrows. Response latencies to congruent trials reflect processing speed, while errors on incongruent trials indicate susceptibility to interference. In this study participants will be presented with two blocks of the MANT - one normal block, and one block with the addition of serial 3s. In the serial 3s block, participants will be asked to count backwards in 3s out loud while continuing to perform the MANT, increasing the level of cognitive demand.
Task Switching TaskBaselineThis task requires executive function and sustained attention, and provides a measure of cognitive flexibility. Participants view a circle with 8 equally spaced radii, 2 of which form a bold bisecting line. Numbers are chosen randomly from a set of 1-4 & 6-9 and displayed sequentially in a clockwise direction. A response of higher or lower than 5 is made for trials below the bold line, and even or odd for numbers above the line. Outcome measures include overall accuracy and reaction time (RT) on correct trials, as well as accuracy and RT on trials where there is a 'switch cost' from stimuli moving from below to above the bold line and vice versa.
Corsi Block Tapping TaskBaselineA standardised assessment of visuospatial working memory. The task comprises nine identical squares fixed in a random arrangement on a screen. Participants observe sequences of between two and nine blocks, which they then reproduce as accurately as possible by clicking with the mouse. Outcomes include number of correct sequences identified as a percentage of accuracy, and number of correct blocks identified (not necessarily in the correct sequence). Four versions of each sequence length are presented during the task. A novel sequence will be presented on each occasion, the order of which will be counterbalanced across participants.
Positive and Negative Affect Schedule (PANAS-X) performanceBaselineA validated self-report measure of affective state. The PANAS comprises of two distinct affective states (positive and negative), as well as 11 individual affective states (fear, guilt, sadness, surprise, hostility, shyness, joviality, self-assurance, attentiveness, fatigue and serenity). Subjects use a Likert scale from 1 - 5 to indicate how the word relates to how they are currently feeling. As this analysis is exploratory all affective states will be explored.
Stress (Perceived Stress Scale)BaselineStress scores will be measured using the Perceived Stress Scale (PSS) at baseline and 4 weeks
Flow mediated dilation (FMD)BaselineParticipants will complete FMD assessment prior to each cognitive task battery (baseline, 2 hours, 4 weeks). FMD is a non-invasive ultrasound technique that measures how the brachial artery dilates in response to increased blood flow following occlusion. Participants are required to lie down for 15 minutes before scanning commences. The procedure then takes 9 minutes: the brachial artery is first scanned for 1 minute, a blood pressure cuff is then inflated on the forearm for 5 minutes, before being released and the artery scanned for a further 3 minutes. This data will be analysed using Cardiovascular Suit. During FMD, laser doppler flowometry (LDF) will also be measured using the index finger of the right arm and analysed for % PORH (post occlusive reactive hyperaemia), measured in flux units .
Blood glucoseBaselineBlood glucose will be measured before each cognitive task battery (baseline, 2h, 4 weeks) using finger prick capillary sampling and an Accu-Chek Instant blood glucose monitor.
Blood pressureBaselineAverage (triplicate) resting brachial left arm cuffed systolic and diastolic blood pressure mmHg.

Other

MeasureTime frameDescription
IQ (Raven's Progressive Matrices)BaselineThe Raven's is a non-verbal intelligence test designed to assess abstract reasoning and fluid intelligence which provides a single score (the sum of correct answers). Ravens will be included in the present study at baseline as a measure of IQ, which may later be utilised as a covariate when analysing the cognitive data.
Habitual diet (Epic-Norfolk Food Frequency Questionnaire)BaselineThe FFQ is a validated tool for gauging the average habitual dietary intake of micro and macronutrients of an individual in the UK. Data will be processed using the FETA software.

Countries

United Kingdom

Contacts

Primary ContactLynne Bell
l.bell@reading.ac.uk01189788313
Backup ContactClaire M Williams
claire.williams@reading.ac.uk0118 378 7540

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026